Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PM 8002

Next Previous
X
Search
Drug Profile

PM 8002

Alternative Names: BNT-327; BNT327/PM8002; PM-8002

Latest Information Update: 23 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotheus
  • Developer BioNTech; Biotheus
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer; Triple negative breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Liver cancer; Malignant-mesothelioma; Neuroendocrine tumours
  • Phase I/II Solid tumours

Most Recent Events

  • 14 Jan 2025 BioNTech plans clinical trials exploring novel combinations of BNT327/PM8002 with ADCs BNT323/DB-1303 (trastuzumab pamirtecan), BNT324/DB-1311 and BNT326/YL202 in 2025
  • 14 Jan 2025 BioNTech plans a phase III trial for Triple-negative breast cancer (First-line therapy) in 2025
  • 31 Dec 2024 Phase-II/III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) (IV) (NCT06712316)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top